309,800 Shares of Bruker Corporation $BRKR Acquired by Brooklands Fund Management Ltd

Key Points

• Brooklands Fund Management acquired 309,800 Bruker shares worth approximately $20.1 million, representing about 0.20% of the company and 3.0% of the fund’s holdings. Institutional investors collectively own 79.52% of Bruker.
• Bruker’s latest quarterly results exceeded expectations, with EPS of $0.49 versus the $0.38 consensus estimate and revenue up 5.2% year over year to $838.5 million. The company reaffirmed fiscal 2026 EPS guidance of $2.10–$2.15.
• Analyst sentiment remains mixed but leans positive: MarketBeat lists a “Moderate Buy” consensus with an average price target of $59.43, while the stock recently traded at $62.00 after reaching a one-year high of $66.98.

Brooklands Fund Management Ltd purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 309,800 shares of the medical research company's stock, valued at approximately $20,060,000. Bruker comprises approximately 3.0% of Brooklands Fund Management Ltd's holdings, making the stock its 16th largest holding. Brooklands Fund Management Ltd owned 0.20% of Bruker as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pallas Capital Advisors LLC acquired a new stake in Bruker in the 2nd quarter valued at approximately $570,746,000. Sculptor Capital LP grew its stake in shares of Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock worth $118,112,000 after purchasing an additional 270,000 shares in the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in shares of Bruker in the second quarter worth $169,899,000. Dimensional Fund Advisors LP increased its holdings in shares of Bruker by 23.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company's stock valued at $84,556,000 after purchasing an additional 448,440 shares during the period. Finally, First Trust Advisors LP increased its holdings in shares of Bruker by 32.5% during the first quarter. First Trust Advisors LP now owns 1,493,053 shares of the medical research company's stock valued at $53,929,000 after purchasing an additional 366,187 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company's stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 27.20% of the stock is owned by company insiders.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $62.00 on Friday. The business has a 50-day moving average price of $58.96 and a two-hundred day moving average price of $50.33. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. Bruker Corporation has a one year low of $32.37 and a one year high of $66.98. The firm has a market capitalization of $9.45 billion, a PE ratio of -88.57, a PEG ratio of 1.90 and a beta of 1.22.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. During the same period in the previous year, the company earned $0.32 earnings per share. The company's revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts predict that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker's dividend payout ratio (DPR) is -28.57%.

Analyst Ratings Changes

BRKR has been the topic of several research analyst reports. The Goldman Sachs Group raised shares of Bruker from a "strong sell" rating to a "strong-buy" rating in a research note on Monday, September 21st. JPMorgan Chase & Co. lowered shares of Bruker from an "overweight" rating to a "neutral" rating and set a $60.00 price target for the company. in a research note on Wednesday, October 14th. Barclays increased their price objective on shares of Bruker from $58.00 to $70.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. UBS Group started coverage on shares of Bruker in a research note on Wednesday, September 9th. They set a "neutral" rating and a $65.00 price objective on the stock. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Bruker in a report on Monday, August 31st. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bruker presently has an average rating of "Moderate Buy" and an average target price of $59.43.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.